TechnoVax

Techno Vax

Biotechnology, 6 Westchester PLZ, Elmsford, New York, 10523, United States, 1-10 Employees

technovax.com

  • LinkedIn

phone no Phone Number: +14*********

Who is TECHNOVAX

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the ...

Read More

map
  • 6 Westchester PLZ, Elmsford, New York, 10523, United States Headquarters: 6 Westchester PLZ, Elmsford, New York, 10523, United States
  • 2003 Date Founded: 2003
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 5046 | NAICS Code: 423450 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from TECHNOVAX

TechnoVax Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding TechnoVax

Answer: TechnoVax's headquarters are located at 6 Westchester PLZ, Elmsford, New York, 10523, United States

Answer: TechnoVax's phone number is +14*********

Answer: TechnoVax's official website is https://technovax.com

Answer: TechnoVax's revenue is $1 Million to $5 Million

Answer: TechnoVax's SIC: 5046

Answer: TechnoVax's NAICS: 423450

Answer: TechnoVax has 1-10 employees

Answer: TechnoVax is in Biotechnology

Answer: TechnoVax contact info: Phone number: +14********* Website: https://technovax.com

Answer: TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: - A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; - An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; - An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access